1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Retracted: The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Advanced Lung Cancer: A Retrospective Cohort Study

      retraction
      Computational and Mathematical Methods in Medicine
      Hindawi

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references1

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Advanced Lung Cancer: A Retrospective Cohort Study

          Objective Lung cancer is a disease associated with high levels of morbidity and mortality, with approximately 2.1 million new cases every year. Anlotinib is a new small-molecule multitarget tyrosine kinase inhibitor independently developed in China that can inhibit the formation of tumor blood vessels and has a therapeutic effect on various cancers. However, the application of anlotinib in lung cancer needs further investigation. Methods We collected the progress notes of 43 patients with advanced lung cancer treated at the Oncology Department of Guangzhou Chest Hospital from March 2019 to March 2021. Additionally, we assessed the differences between drug combination therapy and single-drug therapy among patients treated with anlotinib. Results Patients in both the anlotinib-combination and anlotinib-monotherapy groups experienced remission; however, the overall disease control rate in the anlotinib-combination group was higher than that in the anlotinib-monotherapy group. Reexamination via computed tomography showed that patients in the anlotinib-combination group had better recovery than those in the anlotinib-monotherapy group. Although the overall incidence of adverse reactions in the anlotinib-combination group was higher than that in the monotherapy group, most of the adverse reactions were I–II levels and improved after symptomatic treatment. Conclusion Anlotinib combined with other therapies is better than anlotinib alone for the management of patients with advanced lung cancer.
            Bookmark

            Author and article information

            Contributors
            Journal
            Comput Math Methods Med
            Comput Math Methods Med
            cmmm
            Computational and Mathematical Methods in Medicine
            Hindawi
            1748-670X
            1748-6718
            2023
            1 November 2023
            1 November 2023
            : 2023
            : 9789208
            Affiliations
            Article
            10.1155/2023/9789208
            10631887
            7d7e3a0d-6adc-4cbd-b26d-232a84b32f3b
            Copyright © 2023 Computational and Mathematical Methods in Medicine.

            This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

            History
            : 31 October 2023
            : 31 October 2023
            Categories
            Retraction

            Applied mathematics
            Applied mathematics

            Comments

            Comment on this article